RESULTS	Clinical cure rates for infections caused by methicillin-susceptible ( MSSA ) and methicillin-resistant ( MRSA ) Staphylococcus aureus were 93 % ( 37/40 ) and 92 % ( 35/38 ) for cefdinir vs. 91 % ( 29/32 ) and 90 % ( 37/41 ) for cephalexin ( p > 0.999 comparing treatment groups for MSSA ; p > 0.999 for MRSA ) .\